Tag Archive for: Type 1 diabetes

The FDA recently approved the first cellular therapy for Type 1 diabetes and others may not be far behind. But experts say challenges still exist to the widespread application of these treatments.

Lantidra (donislecel), developed by Chicago-based CellTrans, is a pancreatic islet cell therapy made from the pancreatic cells of deceased donors. It is authorized for adults with type 1 diabetes (T1D) whose repeated episodes of low blood sugar (hypoglycemia) leave them unable to hit average blood glucose levels.

AstraZeneca said on Friday it had signed an agreement with Quell Therapeutics potentially worth more than $2 billion to develop cell therapies that could cure autoimmune diseases.

The new partnership involves an initial payout of $75 million and the potential for up to $2.6 billion in milestone funding.

The buyout will give Sanofi rights over Tzield (teplizumab-mzwv), Provention’s diabetes delay drug, which is the first-ever disease-modifying treatment to delay disease progression.

Genome editing has been a hot-button topic in recent years. With the rise of CRISPR technology in the news, this is not surprising for either scientists or investors.

​​​​​​​The FDA has approved Provention’s BLA for intravenous antibody TZIELD to delay stage 3 type 1 diabetes, making it the first disease-modifying drug indicated to slow disease progression.

Provention Bio entered a co-promotion agreement with Sanofi Thursday ahead of the possible November approval of Type 1 diabetes drug teplizumab.

Imagine Pharma’s founder Ngoc Thai’s ultimate vision for Imagine is to biopsy the pancreases of early Type 1 diabetics, grow out the islet cells, and reinfuse the now insulin-producing cells autologously as a way to treat and almost effectively cure T1D.

Vertex Pharmaceuticals announced Tuesday that the U.S. Food and Drug Administration has lifted its clinical hold on the company’s Phase I/II clinical trial of VX-880, a pancreatic islet cell replacement therapy for people with Type 1 diabetes (TID).